Completed acquisition to become a wholly owned subsidiary and issuance of new shares through a third-party allotment. Payment date is July 1, 2026; issued shares: 9,974,291; issue price: 2,684 JPY per share; funds raised: approximately 26.771 billion JPY. Invested entities: BCP Asia AYM Holding (Cayman) L.P., Toho Holdings, and Hisamitsu Pharmaceutical.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"Ayumi Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/2160-20260701-01.pdf","jir_short_summary":"Completed acquisition to become a wholly owned subsidiary and issuance of new shares through a third-party allotment. Payment date is July 1, 2026; issued shares: 9,974,291; issue price: 2,684 JPY per share; funds raised: approximately 26.771 billion JPY. Invested entities: BCP Asia AYM Holding (Cayman) L.P., Toho Holdings, and Hisamitsu Pharmaceutical.","jir_summary":"### Overview\nToday, Ayumi Pharmaceutical Holdings Co., Ltd. announced that it has acquired all shares of Ayumi Pharmaceutical Holdings Co., Ltd. to become a wholly owned subsidiary. In addition, the payment procedures for the new shares issued through a third-party allotment in connection with an in-kind contribution based on the June 5, 2016 resolution have been completed. The new shares have been allocated to three parties: BCP Asia AYM Holding (Cayman) L.P., Toho Holdings, and Hisamitsu Pharmaceutical, with funding amounting to approximately 26.771 billion JPY.\n\n### Impact on finances going forward\nThe impact on this term's consolidated results is currently under review. Further disclosures will be provided as soon as they are available. The total number of shares after the capital increase will be 65,817,418, which may have dilutive effects on shareholder equity.","jir_financial_highlights":"Number of newly issued shares: 9,974,291 shares (Unknown)\nIssue price: 2,684 JPY per share (Unknown)\nAmount of funds raised: 26,770,997,044 JPY (Unknown)\nTotal issued shares after the capital increase: 65,817,418 shares (Unknown)","jir_category":"","jir_hashtags":"#AyumiPharmaceuticalHoldings, #CapitalPolicy, #JapaneseStocks","jir_key_figures":"Number of newly issued shares: 9,974,291 shares\nIssue price: 2,684 JPY per share\nAmount of funds raised: 26,770,997,044 JPY\nTotal issued shares after the capital increase: 65,817,418 shares\nTotal issued shares before the capital increase: 55,843,127 shares","jir_meta_title":"Ayumi Pharmaceutical Holdings: Completion of All Shares Acquisition and New Share Issuance | July 1, 2026","jir_meta_description":"Announces the completion of Ayumi Pharmaceutical Holdings' wholly owned subsidiary status and the payment completion for new shares issued through a third-party allotment. Allocates 9,974,291 new shares and raises approximately 26.77 billion JPY. Financial impact to be analyzed.","jir_og_title":"Ayumi Pharmaceutical Holdings: Completion of All Shares Acquisition and New Share Issuance | July 1, 2026","jir_og_description":"Announcement of completion of the acquisition and payment for new share issuance. Share count increases and funds amount to about 26.77 billion JPY. Financial impact on future performance is under review.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-74717","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n